Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Synthetic retinoids with anticoagulant effects

Sep. 15, 1997

No Comments

L-374087: a new thrombin inhibitor developed at Merck & Co.

Sep. 12, 1997

No Comments

Heparinase gene covered by U.S., European patents

Sep. 12, 1997

No Comments

YM-60828: an orally active factor Xa inhibitor from Yamanouchi

Sep. 11, 1997

No Comments

Reteplase and alteplase exhibit different profiles of fibrin binding at high doses

Sep. 10, 1997

No Comments

U.S. patent for antithrombotic agents issued to Burnham Institute

Sep. 10, 1997

No Comments

LG Chemical characterizes new thrombin inhibitor

Sep. 10, 1997

No Comments

RPR discloses new factor Xa inhibitors

Sep. 10, 1997

No Comments

Promising phase II results for Genzyme Transgenics' rhATIII

Sep. 9, 1997

No Comments

Novastan granted priority review status by FDA

Sep. 9, 1997

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

BioWorld Science, Hematologic
RSS

Synthetic retinoids with anticoagulant effects

L-374087: a new thrombin inhibitor developed at Merck & Co.

Heparinase gene covered by U.S., European patents

YM-60828: an orally active factor Xa inhibitor from Yamanouchi

Reteplase and alteplase exhibit different profiles of fibrin binding at high doses

U.S. patent for antithrombotic agents issued to Burnham Institute

LG Chemical characterizes new thrombin inhibitor

RPR discloses new factor Xa inhibitors

Promising phase II results for Genzyme Transgenics' rhATIII

Novastan granted priority review status by FDA

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

‘Evo’ AI can design complete genomes

BioWorld Science, Hematologic RSS

BioWorld Science, Hematologic
RSS